Jump to content

Thyroid nodules

From Surgopaedia

A discrete lesion within the thyroid gland

  • Remains a clinical problem to identify which tumours are at risk of causing actual harm to patients if left untreated, and balancing risk of intervention with small risk of the watch-and-wait approach.
  • Approach:
    • USS for TI-RADS
    • FNA for Bethesda
    • Discharge/surveillance/surgery based on Bethesda

Epidemiology

[edit | edit source]
  • In iodine-replete areas:
    • 20-65% of patients will have some sort of nodule if you ultrasound them
    • 5% of women and 1% of men will have a palpable thyroid nodule
  • 5-10% of nodules will be malignant, but the vast majority do not require surgical intervention
  • Diagnosis of thyroid nodules has increased dramatically over the past 30 years, mostly due to the increased pickup rate of <1cm PTCs (microcarcinomas).
  • No change in mortality rate

Risk factors for cancer:

[edit | edit source]
  • History
    • Rapid growth
    • First-degree relative with thyroid cancer
    • Head and neck radiation - takes between 6-35 years to develop into cancer
    • Total body irradiation
    • Thyroid cancer syndromes e.g. MEN-2, FAP, Cowden's disease
    • Young patient <20yo - think medullary cancer, but not necessarily likely to be that
    • Age >70yo
    • Male sex
  • Exam:
    • Fixed, hard mass
    • Obstructive symptoms
    • Vocal cord paralysis
    • Nodules >3-4cm

Pathophysiology

[edit | edit source]
  • Colloid nodules
  • Degenerative cysts
  • Nodular hyperplasia
  • Follicular or Hurthle cell adenomas
  • Malignancies - see separate topic

Presentation

[edit | edit source]
  • Majority benign and asymptomatic
  • Consider features of hyper-functioning/toxic nodule (hyperthyroidism - see separate topic)

Initial investigation

[edit | edit source]
  • TFTs: TSH, T3/T4
  • Calcium, PTH, vitamin D
  • Optional: (mostly if TSH is abnormal)
    • TRABS - exclude Graves disease
    • Anti-TPO Ab - Hashimoto's
    • Thyroid antibodies
    • Calcitonin - only if suspected medullary cancer
    • Genetic testing - e.g. BRAF

Imaging:

[edit | edit source]
  • USS first-line:
    • Nodules picked up on examination
    • Incidental nodules found through other modalities
  • CT to evaluate for retrosternal extension or metastases - don't generally give IV contrast, since it will preclude the ability to give radioactive iodine
  • Nuclear medicine thyroid scintigraphy
    • Indication - hyperthyroidism and thyroid nodule
    • Looking for a toxic nodule
  • Incidental PET-positive nodule has quite a high rate of malignancy - exact number varies from study to study - could say 40%
    • Have a lower threshold to biopsy rather than purely following TIRADS
    • ATA guidelines suggest biopsy anything PET-positive >1cm (equivalent to TR5). They will almost always be >1cm to show up on PET anyway.
    • Differentials: colloid nodule, follicular adenomas (functioning and non-functioning), MNG, nodular thyroiditis (subacute and chronic lymphocytic), degenerative thyroid cyst, malignancy, parathyroid, lipoma, paraganglioma, very rarely infiltrative disorders (e.g. haemochromatosis)


Ultrasound findings:

  • Look at: (those in bold have higher specificity for cancer)
    • Echogenicity (hypoechoic is suspicious)
    • Calcifications and microcalcifications
    • Shape (taller than wide, with irregular margins - since malignancies tend to cross tissue planes)
    • Vascularity
    • Composition
    • Nodes
    • Reassuring for benign - spongiform pattern, purely cystic appearance
  • Elastography (measuring stiffness of thyroid nodule using USS) is not currently recommended for routine use



TI-RADS:

Composition Echogenicity Shape Margin Echogenic foci
Cystic or almost completely cystic 0 Anechoic 0 Wider-than-tall 0 Smooth 0 None or large comet-tail artifacts 0
Spongiform 0 Hyperechoic or isoechoic 1 Taller-than-wide 3 Ill-defined 0 Macrocalcifications 1
Mixed cystic and solid 1 Hypoechoic 2 Lobulated or irregular 2 Peripheral (rim) calcifications 2
Solid or almost completely solid 2 Very hypoechoic 3 Extrathyroidal extension 3 Punctate echogenic foci 3
Points Malignancy risk (%) Biopsy threshold (mm)
TR1 0 0.3 No biopsy
TR2 2 1.5 No biopsy
TR3 3 4.8 25
TR4 4 to 6 9.1 15
TR5 7+ 35.0 10


ATA:


Can use ATA score or TI-RADS for risk-stratifying thyroid nodules. Both independently validated but TI-RADS currently thought to be better.

  • These will decide whether or not to proceed with FNA
  • Also incorporate clinical assessment - FNA can still be considered in nodules <1cm or not otherwise meeting criteria with:
    • Strong family history thyroid cancer
    • Young patient
    • Therapeutic head and neck radiation
    • Preference for FNA over observation
    • Location of nodule in thyroid
    • Lymphadenopathy
    • Immobile, fixed mass with voice changes

Cytopathological risk stratification

[edit | edit source]
  • FNA is preferred technique - gives good enough answer to render larger biopsies such as CNB obsolete, unless lymphoma is a high possibility
    • Can technically be done blind, but USS-guided is obviously better
    • Mean sensitivity >80%, mean specificity >90%
    • 23-27-gauge needle
    • Confirm adequacy of specimen at time of biopsy (6 groups of well-visualised follicular cells, 10 cells per group)
  • Contraindications to FNA:
    • Prohibitive surgical risk
    • Already proceeding with thyroidectomy
    • Extreme elderly with small nodules
  • Use BETHESDA system for thyroid cytopathology (last updated 2017; below)
    • Categories 2 and 6 are highly accurate, with error rate <3%
    • Others quite variable - see ranges of malignancy below
    • Traditional recommendation for 3 and 4 lesions to have lobectomy, but efforts now to reduce that rate, since most are benign. Molecular testing may help.
  • Molecular testing
    • Complex field. Tests can be considered as either 'rule-in' or 'rule-out' tests.
    • Most useful for Bethesda 3 and 4 nodules
    • Take into account the holistic picture and order appropriately.
    • Afirma Gene Expression Classifier - mostly rule-out - 90% sensitivity, but specificity 50% for Bethesda 3 and 4 nodules
    • Afirma Genomic Sequence Classifier - se 91% sp 68%. Particularly poor performance for Hurthle cell adenoma and carcinoma.
    • ThyroSeq v2 - se >90% sp >90% in early studies, but subsequent validation outcomes were poor.
    • ThyroSeq v3 - se 94% sp 82% in Bethesda 3 + 4, and better performance in Hurthle cell. Costs about $2,100 per nodule in Australia, with no medicare rebate, and takes a couple of weeks.
Bethesda class Diagnostic category Cancer risk
I Nondiagnostic (unsatisfactory) 5 to 10%
II Benign 0 to 3%
III Atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS) 10 to 30%
IV Follicular neoplasm (or suspicious for follicular neoplasm, also encompassing Hurthle cell neoplasm) 25 to 40%
V Suspicious for malignancy 50 to 75%
VI Malignant 97 to 99%
  1. Repeat FNA, then excisional biopsy if still indeterminate
    1. Some surgeons say 2x FNA then 1x core biopsy then consider excision
  2. Repeat follow-up 2-3 years is probably standard for these nodules
  3. Cancer risk is overstated for this group. Consider clinical and radiographical factors (as in, were you expecting a higher Bethesda score based on the TI-RADS?). Consider repeat FNAB or lobectomy.
  4. Typically excised. Mostly found to be follicular adenomas or adenomatoid nodules of MNG. Can't tell the difference between benign and malignant follicular lesions on FNA - need to see whether there is capsular invasion.
  5. Surgical resection
  6. Surgical resection, unless widely metastatic.

Management options

[edit | edit source]
  • Discharge
  • Surveillance
  • Surgery

Management of thyroid nodules in pregnancy

[edit | edit source]
  • If symptomatic of severe compression - immediate surgery
  • If asymptomatic, USS and FNA as usual
    • Well-differentiated cancer could have second trimester surgery or defer until post-partum, depending on risk profile
    • Anaplastic or MTC would generally have immediate surgery
    • Suspicious FNA could either have second-trimester surgery or deferred workup

Follow-up for nodules that don't meet FNA criteria/benign

[edit | edit source]
  • <1cm with suspicious characteristics: 6-12 months
  • Low-intermediate suspicion on USS - 12-24 months
  • Very low-risk nodules: 2-3 years
  • Benign: 1-3 years depending on risk factors
  • 2x FNAs with both benign: No further USS indicated

Surgery

[edit | edit source]
  • Indications for surgery:
    • Concern for malignancy
    • Hyperfunction
    • Local compressive symptoms
  • Lobectomy vs thyroidectomy (ATA guidelines 2016)
    • >4cm differentiated cancer: total thyroidectomy
    • 1-4cm without clinical evidence of extrathyroidal disease or nodal mets or high-risk features: Either total thyroidectomy or lobectomy are appropriate. Controversial.
    • <1cm: surveillance or lobectomy
  • Favour total thyroidectomy in
    • Age >45
    • Contralateral thyroid nodules
    • Hx radiation exposure
    • Familial DTC
    • Patient preference

Follow-up post-op:

[edit | edit source]
  • Note that following lobectomy, if pathology is malignant, TSH will need to be maintained <2mIU/L